Abstract: The present disclosure discloses a tobacco leaf foliar spraying substance for reducing harmful ingredients in cheroot, a method for reducing carcinogenic components in flue-cured tobacco leaves and flue-cured tobacco shreds. The tobacco leaf foliar spraying substance contains a lotus leaf extract, the harmful chemical ingredients comprise N-nitrosonornicotine, 4-(N-methyl-nitrosamine)-1-(3-pyridinyl)-1-butanone, N-nitrosoanabasine and N-nitrosoanatabine. Foliar spraying is performed on a fertile field by using the lotus leaf extract before tobacco leaves are harvested and modulated, which not only significantly promotesagronomic characters and economic traits of tobacco and alleviates tobacco leaf browning but also effectively reduces harmful chemical ingredients unique to tobacco leaves, such as nitrosamine and nicotine.

Abstract: A granulated defoamer has a dry ammonium sulfate which has been combined with a mixture of at least two of the following materials, anionic surfactant, an organic acid and a defoamer. The method of creating the granulated defoamer and method of using the same in agricultural spraying of vegetation.

Abstract: This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions containing such molecules, and processes of using such pesticidal compositions against such pests. These pesticidal compositions may be used, for example, as acaricides, insecticides, miticides, molluscicides, and nematicides. This document discloses molecules having the following formula (“Formula One”).

Abstract: The invention provides a topical o/w emulsion which moisturizes, and protects, repairs or restores the skin lipid barrier of a mammal. The topical o/w emulsion composition comprises: (a) a discontinuous oil phase; (b) a continuous aqueous phase comprising water; (c) a thickening agent; (d) at least one lamellar membrane structure comprising (i) a phospholipid, (ii) a fatty alcohol, and (iii) a fatty acid; and wherein in use the composition has a water vapor transmission rate of less than about 70 g.m?2.hr?1 measured in vitro using the modWVTR test methodology.

Abstract: New natural-based, eye make-up cosmetic composition, comprising graphene, being free from synthetic polymers, provided with optimal features for ease of distribution and high-definition.

Abstract: The present disclosure relates to rheology modified, low foaming aqueous antimicrobial compositions. The compositions are phase stable under acidic conditions, and do not need to be rinsed from the surface to which they are applied. The present disclosure further relates to methods of use thereof.

Abstract: Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.

Abstract: The invention provides for a topical o/w emulsion having moisturizing, and protecting, repairing or restoring the skin lipid barrier of the lips of a mammal, and is a topical oil-in-water emulsion composition comprising: (a) a discontinuous oil phase; (b) a continuous aqueous phase comprising water; (c) a thickening agent; (d) at least one lamellar membrane structure comprising (i) an alkyl amphiphilic component, (ii) an ester of a branched fatty acid and a branched fatty alcohol, (iii) a fatty acid, (iv) a fatty alcohol, and optionally (v) a phospholipid; and wherein in use the composition has a water vapor transmission rate of less than 65 g·m?2·hr?1 measured in vitro.

Abstract: Described is a method for the production of substantially spherical calcium phosphate particles that involves subjecting a composition comprising calcium phosphate to dual asymmetric centrifugation (DAC). Also described are products of the method.

Abstract: The present invention relates to a novel pharmaceutical composition comprising doxycycline for topical application, in particular to the eye and eyelids. The invention also relates to this topical composition for use in the treatment of bacterial infections of the skin and mucous membranes.

Abstract: In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.

Abstract: A solid temporal colorimetric hydrogel cosmetic composition includes 15 to 99.90 wt % of the water phase part and 0.10 to 85 wt % of the oil phase part, having a refractive index difference of 0 to 0.02 therebetween, and having a color change according to variations in a refractive index difference between the water phase part and the oil phase difference when applied to the skin. The cosmetic composition not only has flexibility through irradiation of gamma-rays, but also enables an optimal application time of the cosmetic composition to be visually confirmed through a color change from transparency to ivory white due to a change in the refractive index difference caused by absorbency and volatilization of water when applying the composition to the skin. The cosmetic composition is capable of improving quality of a product although a preservative irritating to the skin is not added.

Abstract: This disclosure provides, among other things, compositions comprising quantities of oltipraz crystals, as well as method of making such compositions, and method of treating patients using such compositions. Taste-modified compositions also are provided.

Abstract: A particulate plug for removing a preservative from a solution, suspension, or emulsion comprising a drug is presented. The plug comprises microparticles of a hydrophobic polymer/fatty acid blend. The microparticles of hydrophobic polymer/fatty acid blend selectively absorb preservative allowing the drug to remain in solution for delivery.

Abstract: In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.

Abstract: The present invention relates to an oral soluble film (OSF), methods of orally administering the same, and methods of manufacturing the same. The oral soluble film includes sildenafil citrate, and can further include a binder, filler, flavoring agent, plasticizer, sweetening agent, preservative, solvent, and optionally coloring agent. The active ingredient and excipients can be provided and present in an amount effective to achieve desired physical and performance characteristics of the OSF.

Abstract: Oral formulations for promoting eye health, and in particular for preventing or treating macular degeneration, are disclosed, containing zeaxanthin, a carotenoid pigment, and at least two or more additional ocular-active nutrients selected from lipoic acid, omega-3 fatty acids, plant-derived compounds such as flavonoids, anthocyanins, or polyphenolics, taurine, carnitine, Coenzyme-Q10, carnosine, and nutrients that stimulate the production of glutathione. Processes are disclosed for identifying ocular-active nutrients that will interact in a synergistic and potentiating manner with zeaxanthin, to provide better and more effective protection, for eye health, than can be provided by zeaxanthin alone. Additional optional agents include zinc, vitamin E, and vitamin C.

Abstract: Novel biaromatic compounds, which are vitamin D analogs, processes for their preparation and cosmetic, dermatological and pharmaceutical preparations containing one or more of these compounds.

Abstract: The invention provides methods and compositions for treating and/or preventing chlorine-gas induced lung injury with sodium thiosulfate.

Abstract: A method of treating blepharitis includes administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient consists essentially of a glucocorticoid in an ophthalmically acceptable vehicle that includes an aqueous polymer suspension that when mixed with tear fluid provides a sustained release of said active ingredient. The aqueous polymer suspension includes a carboxyl-containing polymer having less than about 5% by weight cross-linking agent and has a viscosity in a range from about 1,000 to about 30,000 centipoises. A kit includes: (a) a composition comprising about 0.1% by weight dexamethasone in this ophthalmically acceptable vehicle and (b) instructions for using the composition of (a) for the treatment of blepharitis.